Recursion Pharmaceuticals (RXRX) Stock Price
$5.5 3.4%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
1 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals' last reported revenue was $4.5M, representing a significant decrease of -82.7% from the previous quarter and -67.3% YoY. The company's gross profit was negative at -$8.3M, showing a substantial decline of -159.2% QoQ and an alarming drop of -972.9% YoY. Their operating income also showed a negative trend with -$183.8M, down by -86.8% QoQ and by -90.7% YoY.
The EBITDA ratio stood at -36.65 in the last quarter, indicating financial instability or high growth investment depending on the context.
Stock Price
The current stock price is $5.76 which shows a downward trend as it has decreased by -9.3% over the past month and significantly dropped by -31.% over the past year.
The RSI value is 50.1 suggesting that the stock is neither overbought nor oversold while its 200-day moving average stands at $6.96 which indicates that it's currently undervalued when compared to its historical trend.
Alternative Data Signals
Web traffic for Recursion Pharmaceuticals has seen a slight decline with an estimated 60440 visitors per month, down by -11%. Job openings have also decreased substantially by about half both MoM (-55%) and YoY (-50%). Despite this, employee sentiment seems positive with an estimated 79% reporting a positive business outlook.
Social media presence is growing with Twitter followers up by 62%, reaching to around 14k followers in the last three months and Facebook following increasing modestly by 13.5% to reach nearly 700 followers.
Conclusion
Given the significant declines in financial performance and stock price, along with mixed signals from alternative data sources, the AI analysis of Recursion Pharmaceuticals' stock is bearish.
Note: This AI Stock Analysis is based on data as of April 12. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.5, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.2B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$22.52 1.5% |
5 |
 |
Inovio Pharmaceuticals INO |
$1.74 1.2% |
1 |
 |
Moderna MRNA |
$24.72 1.9% |
3 |
 |
Anavex Life Sciences AVXL |
$8.95 1.2% |
5 |
 |
BridgeBio Pharma BBIO |
$33.87 0.1% |
4 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 60440 monthly visitors to recursion.com.
-
Web Traffic
60440
-
Change from Previous Month
11.9%
-
3 Month Change
5.5%
-
YoY Change
5.5%
News Mentions
Recursion Pharmaceuticals was mentioned 2 times in the news yesterday.
-
News Mentions
2
-
Daily Change
33.3%
-
1 Month Change
0%
-
3 Month Change
100%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
Twitter Followers
Recursion Pharmaceuticals has 14,106 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.8% over the last month.
-
Twitter Followers
14106
-
Daily Change
0%
-
1 Month Change
0.8%
-
3 Month Change
5.8%
-
YoY Change
5.8%
Facebook Engagement
Recursion Pharmaceuticals has engaged 13 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
13
-
Daily Change
0%
-
1 Month Change
116.7%
-
3 Month Change
23.5%
-
YoY Change
23.5%
Youtube Subscribers
Recursion Pharmaceuticals has 3,550 subscribers on its main Youtube channel, up by 1.4% over the last month.
-
Youtube Subscribers
3550
-
Daily Change
0%
-
1 Month Change
1.4%
-
3 Month Change
14.9%
-
YoY Change
14.9%
Job Postings
Recursion Pharmaceuticals has an estimated 22 open job postings, which is down -65.6% over the last month.
-
Job Postings
22
-
Daily Change
8.3%
-
1 Month Change
65.6%
-
3 Month Change
59.3%
-
YoY Change
59.3%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 79 out of 100 (bullish).
-
Business Outlook
79
-
Change from Previous Month
1.3%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$4.5M
-
Net Income
-$178.9M
-
Earnings per Share
-$0.53
-
Free cash flow
-$117.1M
-
EBITDA
-$165.3M
-
EBITDA Ratio
-36.6533
-
Total Assets
$1.4B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $5.5.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.2B.
Should I buy or sell RXRX?
Recursion Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Recursion Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Recursion Pharmaceuticals a good investment?
The current analysis of Recursion Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Recursion Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Recursion Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $5.19 in 2026. Starting from the current price of $5.5, this represents a 5.6% change in price, indicating a bearish outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.